AnodyneWiki

Mianserin

Mianserin
Mianserin
Salts
[]
Mianserin hydrochloride
Mianserin hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass264.40 g/mol [1]
Solubility2.32e-01 g/L [1]
Predicted LogP3.4 [1]
Structural Identifiers
[]
Molecular formulaC18H20N2
IUPAC name5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
SMILESCN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
InChIInChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
InChIKeyUEQUQVLFIPOEMF-UHFFFAOYSA-N
CAS number24219-97-4
UNII250PJI13LM
PubChem CID4184
Pharmacokinetics[]
Elimination half-life21–61 hours
MetabolismLiver (CYP2D6; via aromatic hydroxylation, N-oxidation, N-demethylation)
ExcretionUrine: 4–7%, Feces: 14–28%
Routes of administrationBy mouth

Mianserin (also known as Mianserine, Mianserina, Mianserinum, Tolvon, 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine, J16.389i, Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine, Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- or 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine) is a substance of the phenethylamine class.

Chemistry

Salts []

Mianserin is typically found in the form of its hydrochloride salt.

 []

Mianserin is a racemic mixture of the (optical activity ( + / - )).

Stereoisomers from PubChem

Mianserin matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

induction / metabolism / inhibition74 (2 contraindicated)
inhibition / metabolism / induction16 (1 contraindicated)
metabolism / induction / inhibition12 (2 contraindicated)
shared target3 (1 contraindicated)
shared target3 (1 contraindicated)
shared target3 (1 contraindicated)
shared target1

Medical side effects []

69 side effects listed on drug labels in (mianserin).

  • Headache
  • Tremor
  • Diplopia
  • Nasal congestion
  • Neuroleptic malignant syndrome
  • Paraesthesia
  • Restless legs syndrome
  • Convulsion
  • Agitation
  • Hyperkinesia
  • Bradycardia
  • Agranulocytosis
  • Anaemia
  • Arthralgia
  • Musculoskeletal discomfort
  • Myalgia
  • Arthritis
  • Asthenia
  • Fatigue
  • Mental disorder
  • Breast disorder
  • Confusional state
  • Feeling abnormal
  • Connective tissue disorder
  • Constipation
  • Dizziness
  • Syncope
  • Somnolence
  • Oedema
  • Dermatitis
  • Rash
  • Eye disorder
  • Gastrointestinal disorder
  • Gynaecomastia
  • Cardiac arrest
  • Cardiac disorder
  • Cardiac failure
  • Blood disorder
  • Hepatitis
  • Hypertension
  • Hypotension
  • Jaundice
  • Lethargy
  • Leukopenia
  • Mediastinal disorder
  • Nervous system disorder
  • Neutropenia
  • Pancytopenia
  • Bone marrow depression
  • Pruritus
  • Shock
  • Loss of consciousness
  • Tachycardia
  • Thrombocytopenia
  • Tinnitus
  • Torsade de pointes
  • Angiopathy
  • Vertigo
  • Weight increased
  • Dry mouth
  • Depressive symptom
  • Hepatic function abnormal
  • Electrocardiogram QT prolonged
  • Skin disorder
  • Hepatic enzyme increased
  • Hypomania
  • Erectile dysfunction
  • Hepatobiliary disease
  • Suicidal ideation

Indications

  • Major depression

 []

  • Australia: Mianserin is a Schedule 4.
  • Brazil: Mianserin is a C1.[3]
  • United Kingdom: Mianserin is Prescription only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4184, Mianserin. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4184
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Mianserin. UNII: 250PJI13LM. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/250PJI13LM
  3. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 19:00:33
drugspromissing (no DrugsPRO reagent data)2026-11-20 19:00:29
erowidmissing (no Erowid substance of that name)2026-11-20 19:00:29
gsrsok2026-11-20 19:00:30
hmdbmissing (hmdb.ca refused automated access to HMDB0015620)2026-11-20 19:00:29
keggok2026-11-20 19:00:31
pubchemok2026-11-20 19:00:27
redditmissing (no r/tripreports posts mention it)2026-11-20 19:00:29
siderok2026-11-20 19:00:29
structureok2026-11-20 19:00:29
wikipediaok2026-11-20 19:00:29